At a glance
ClinicalIndex Comparison RecordN/ACompleted· 150 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective Multicenter Study to Observe the Effectiveness on Ulcerative Colitis and Predictive Factors of Clinical Response in Korean Patients Treated With Adalimumab (EUREKA Study)
In Brief
An observational study for Ulcerative Colitis. Completed, enrolled 150 participants across 19 sites.
Detailed Summary
This is a prospective, single country, multi-center study in participants with ulcerative colitis (UC) treated with adalimumab. Up to 147 participants are enrolled at approximately 20 sites. The baseline assessment is performed prior to the first dose of adalimumab (Visit 1). Study visits are conducted at weeks 8, 16, 24, 32, 40, 48 and 56 after baseline in accordance with clinical practice. All participants will have one Follow-up for safety approximately 70 days after the last dose of adalimumab.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsUlcerative Colitis
CountriesSouth Korea
Collaborators--
Timeline
N/ACompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartJun 2015
First PostedJul 2015
Primary CompletionSep 2018
TodayJul 2026
First PostedJul 16, 2015
Enrollment StartJun 11, 2015
Primary CompletionSep 17, 2018
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 11.0 years ago